Compare ARK Genomic Revolution ETF (ARKG) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Invesco S&P 500 Momentum ETF — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Invesco S&P 500 Momentum ETF trades at $151. Which is the better fit depends on your goals.
| ARKG | SPMO | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $43.57 | $161.66 |
52-Week Low | $23.09 | $107.84 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
SPMO trades at $153.75, up 0.44% today, with a neutral technical signal. Momentum factor performance remains strong, gaining 7.5% in June 2026. The ETF's concentrated technology exposure (55%) drives returns but increases volatility. Support lies at $152, resistance at $155. Recent news highlights momentum's dominance in Q2 2026 with a 44.4% gain.
Outlook remains positive due to AI-driven momentum, though high sector concentration poses risks during market rotations. Analyst sentiment is generally bullish, but investors should monitor for signs of momentum fatigue or broader market pullbacks that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
